This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
And delays in the supply chain, even for short periods of time can potentially affect the efficacy of medicines, lead to longer-term supply bottlenecks, and ultimately prevent people from getting access to the critical medicines they need. Consumers are taking notice of these metrics, and there is demand for action from pharma.
Increasing diagnosis of chronic diseases is expected to lead to fast growth in retail pharmacies. Integrating AI into the operations of retail pharmacies helps in improving the decision-making process, order fulfilment, demand forecasting, and monitoring of the transportation and storage environment.
Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases.
Pharmaceutical Technology has listed some of the leading wholesalers of pharmaceutical products based on its intel, insights, and decades of experience in the sector. The post Leading pharmaceutical wholesalers appeared first on Pharmaceutical Technology. Discover the top pharmaceutical wholesalers. GDP and GMP advisory.
French biopharmaceutical firm Ipsen has concluded the purchase of US-based Albireo Pharma , expanding its rare disease portfolio. Albireo’s pipeline includes its lead asset, Bylvay (odevixibat), a potent, once-a-day, oral, non-systemic, ileal bile acid transport inhibitor (IBATi).
When people think about pharma, they often think about “big” pharma: large, faceless corporations. Every pharma company developing treatments for new diseases is contributing to some degree to better global health. But Giacomo Chiesi, head of Chiesi Global Rare Diseases, thinks of his 6,000-person company as a family business.
In a letter to energy ministers, they stated that raw material prices have risen by as much as 50–160% and transportation costs by up to 500%. It also stresses that some pharma manufacturers are at risk of having gas rationed or being unable to continue manufacturing due to high prices.
Cold chain – a vital part of medical logistics Cold chain refers to the transportation and storage of temperature-controlled medications. The investment will enable an estimated 150 medical-grade refrigeration units to be installed at 25 Life for a Child partner facilities in Africa, Latin America, the Caribbean and Southeast Asia.
Tablets were noted to be the most common form of OSD in 2021 because of their convenience and simplicity in production, transportation and delivery to the end user. Leading companies in the oral solid dosage market are Catalent, Inc., This is especially beneficial as a way of decreasing potential side effects.
Challenges in the pharmaceutical supply chain Pharmaceutical supply chain issues include long transportation distances, low transparency of inventory levels and cargo theft. These can lead to inventory shortages, the paper noted. For instance, these drugs must be equipped with real-time insights.
Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). Clinical studies have demonstrated its potential in regulating genes involved in bile acid synthesis, inflammation, fibrosis and lipid metabolism, storage, and transport.
Primary packaging for vaccines As one of the pharmaceutical divisions of the Group, IMA Life leads the global market, taking care of the design and development of complete aseptic lines for parenteral products with or without freeze-drying requirements. Isolation technologies and other containment solutions are also part of our expertise.
Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. This major difference leads to very different requirements and processes for the clinical trial supply chain, which are summarized below.
Credit: IMA Pharma – AQUARIA The Continuous Direct Compression Line (CDC Line), a very lean, efficient and flexible tablet-manufacturing technology that, in combination with PAT, allows easy adoption of a QbD approach, ensuring excellent operation performance and avoiding waste during startup and shutdown.
Compromising on quality might save a few bucks initially but can lead to a tattered, unprofessional look that does more harm than good in the long run. A chaotic bag can lead to a chaotic presentation. Ease of Transport: Comfort and Convenience Sales reps are often on the move, so ease of transport is a critical feature.
Amgen buying Horizon Therapeutics and Ipsen ’s acquisition of Albireo Pharma show an increased appetite for investment in therapies for rare diseases. The mutation leads to disordered thyroid hormone transport, which causes patients to experience intellectual and motor disabilities. This was not always the case. “Up
Jay Patel From our experience in patient research across many different treatments, we’ve defined several key insights on what may lead to nonadherence: Complex medication routines and patients feeling overwhelmed with their regimen. Inconvenient or challenging-to-adhere-to medications that have complex administration methods.
The industry has been limited in its ability to implement creative solutions to engage and motivate patients because the FDA has strict guidelines for what pharma companies can communicate with patients. Yet, pharma companies spend more than $5 billion on patient support programs every year, and only 3% of patients are using them.
To find out, PM360 asked experts within patient groups, pharma companies, and other industry partners: What are the keys to building trusting and mutually beneficial partnerships? do rare disease patients and advocacy groups most value or need from pharma? So, what are the keys to working with these groups?
Uniquely positioned, traditional patient access hubs promise to simplify the process of getting patients started on therapy and offer to provide HCPs with much-needed assistance in navigating payer requirements leading up to therapy starts. Technology is upending every aspect of our lives, from retail to transportation.
After more than two years of pandemic restrictions, many Pharma leaders are itching to meet with their key opinion leaders (KOLs) face-to-face again, believing that’s what most KOLs want. J unior or less verbose KOLs often do not get the same opportunity to participate , leading to strategic blindspots and missed opportunities.
These developments, together with Walgreens’ recent rollout of Health Corners that help patients manage chronic conditions and its October 2022 announcement that it would fully acquire CareCentrix (a platform that coordinates post-acute and home care), underscore Walgreens’ plans to become a leading healthcare provider. The post U.S.
Companies must adhere strictly to laws and regulations related to drug safety and maintain stringent quality control procedures throughout every step of production, packaging, transportation, storage, and distribution – all the way through dispensing at the pharmacy level. About the Author David L.
This can lead to severe health risks for the patient, in which case the pharmacy would be held liable. About the author Ataa Elfaquih is the Global Quality Director for the Pharma and Healthcare unit of Mayr-Melnhof group and a recognised expert in quality management with significant experience in the field.
Once in the bloodstream, it is transported to its target tissues, inhibiting enzymes (like COX-2) that cause pain and inflammation. Therapeutic drug monitoring is used to obtain peak and trough levels to determine drug serum concentration which tells us if a drug is efficacious or is leading to toxic levels. metformin). metformin).
Household names are leading the way. Meanwhile, GlobalData figures show that new job postings within pharma relating to social responsibility in the third quarter of 2022 grew by 10% quarter-on-quarter – and a whopping 161% year-on-year. It is a trend that shows no signs of slowing down. It is projected to increase even further.
Errors including delays and temperature excursions can have significant public health and financial consequences, leading to unsafe products, liability issues, and costly rejections. Resilient pharma companies using advanced technologies and embracing digital transformation will be better equipped to adapt and thrive.
The panel consisted of leading life science industry experts, amongst which included: Bhash Parasuraman, Ph.D., That was the case for Karius, whose partnership with Clarify was dependent on securing a thought partner with robust data analytics capabilities, proven transparency, and industry-leading data visualizations.
Quantitative survey results can often lead to a false sense of security around pre-selected response options, therefore missing critical contextual information that helps someone truly understand the patient’s perspective. This sub-set of office personnel is valuable and often leads to rich insights if marketers can spend the time/money.
Outside of the frail and elderly, high-risk patients could also be those who are unable to reliably practice social distancing because of crowded living conditions, inability to stay home if they are essential service workers, and/or the need to take public transportation regularly.
Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinical trials. Yet in the period analysed, GlobalData recorded just 24 clinical trials for sickle cell diseases in the region.
Supply chain shortages have dominated headlines for several months, and the pharma industry has been no exception. And while there are occasional discussions about pharma companies re-shoring API production facilities, the process would be extremely expensive and complex. Maxine Fritz, executive vice president, Pharma Biotech, NSF.
This issue was further complicated by the leading development efforts being mRNA vaccines, with large-scale capacity not existing and therefore had to be scaled up extremely rapidly. The same operation also made significant investments in companies providing ancillary COVID-19 vaccine supplies , such as the production of needles and syringes.
LEAD-IN: Yesterday I had a long talk with someone who has been in the industry for over 25 years. She has decided to leave the pharma industry because she said, “patients have been reduced to numbers on an excel spreadsheet” and “I am tired of trying to get coworkers to see them as people with real needs.”
Pharma will be focusing more on relevant research, support, and a better mix of non-promotional and promotional interaction. Given the funding environment for innovative medicines that is faced by all pharma, large or small, once assets are approved, however, this 2023 reset seems a necessary response.
The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. Are you intrigued to know what technologies will rule the pharma market and how they can benefit your business in 2023? from 2022 to 2030, the pharma industry will reach USD 9,241.34 billion during 2020-2024.
Peptides have a longer shelf life due to their simplicity and ease of transport. In terms of application diversity, Ascentawits Pharmaceuticals is the top company, followed by OBI Pharma and Mabwell Shanghai Bioscience. By means of geographic reach, Onxeo holds the top position.
The end-to-end supply chain comprises material procurement, manufacturing, transportation, warehousing, and distribution. Furthermore, quality oversight overseas is often less stringent and can lead to safety problems, adverse regulatory actions, and production halts or recalls.
Ties Kroezen, venture leader of Community Life Centers and business development manager for Philips Africa, tells us about the challenges present within the African healthcare system, solutions the company developed to help patients and providers connect, and how pharma can assist with delivering better care to African residents.
Hospitals, clinics, pharmacies, wholesalers of medical products and other health centres are catered by pharmaceutical logistics that include handling activities such as procurement, warehousing, and inventory management, as well as transportation, and management of the supply chain for diverse products.
They can transform, simplify, and automate processes to reduce lead times, improve sustainability, and minimise cost. Compared to other industries, pharma has been slow to adopt AI, but there has been increased activity over the past few years. Pharma also plans to invest in AI in the near future.”
Conference agenda highlights CPHI Milan will present a comprehensive conference agenda on topics such as sustainability and pharma, next generation mRNA vaccines, European regulation, biomanufacturing, and more. Pharma is often considered innovation-limited beyond core R&D.
That was always something we talked about as I was managing managers and leading leaders. Patients, caregivers, and the reps, everybody but when you zoom out and think of healthcare, particularly in the United States for sure, you’ve got nursing and transport. Transitioning from pharma to med device. They have needs.
It encompasses everything: navigating insurance, finding transportation to appointments, interpreting test results via online portals, and much more. That means pharma must integrate their touchpoints into a new care journey with both patients and providers experiencing and delivering care differently.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content